Key Takeaways:
- Semaglutide reduced heavy drinking days by 41.1% compared to 26.4% with placebo in a major Lancet trial
- 108 participants with alcohol use disorder and obesity completed the 26-week study, with 81% finishing the full intervention
- A Phase 3 VA trial testing semaglutide for alcohol use disorder began enrolling U.S. veterans on May 1, 2026
A groundbreaking study published in The Lancet on May 2, 2026, has shown that semaglutide (the active ingredient in Wegovy and Ozempic) demonstrated strong therapeutic benefits in individuals with obesity and alcohol use disorder who were actively seeking treatment. The findings represent a potential paradigm shift in how we treat one of the most challenging addiction disorders.
Alcohol use disorder accounts for 5% of deaths worldwide annually, and there is an urgent need for new therapeutic interventions. For decades, treatment options have been limited to three main medications — naltrexone, acamprosate, and disulfiram — alongside therapy and support groups. This new research suggests GLP-1 medications could offer a powerful addition to the treatment arsenal.
The Danish Study Results
The randomized, double-blind, placebo-controlled trial conducted at Mental Health Center Copenhagen included 108 participants (53 women and 55 men) enrolled from June 10, 2023, to Feb 4, 2025. All participants had both alcohol use disorder and obesity, with a body mass index of 30 kg/m² or higher.
Notably, 85% of participants met criteria for severe alcohol use disorder, with a mean of 17 heavy drinking days per month and mean alcohol consumption of about 2,200 g over 30 days. This represents a population with serious addiction issues, making the results even more significant.
Participants received either semaglutide 2.4 mg once weekly or placebo, and both groups were offered up to 10 sessions of cognitive behavioral therapy. The results were striking: semaglutide was associated with a reduction in heavy drinking days of 41.1 percentage points from baseline compared with placebo at 26.4 percentage points.
The treatment difference of 13.7 percentage points was statistically significant and represents meaningful clinical improvement. The glucagon-like peptide-1 receptor agonist also had substantial effects on secondary alcohol-related and somatic outcomes.
How GLP-1 Drugs May Work for Addiction
The mechanism behind these effects extends beyond appetite suppression. Preclinical and initial human studies indicate that the GLP-1 receptor agonist semaglutide might reduce alcohol drinking. Researchers believe GLP-1 receptors in the brain's reward pathways may be involved in addiction behaviors, not just metabolic regulation.
Previous observational studies have shown reduced desire to drink in those treated with semaglutide, and this retrospective cohort study of 83,825 people with obesity showed that semaglutide compared with other anti-obesity medications is associated with a 50%-56% lower risk for both the incidence and recurrence of alcohol use disorder.
Side effects in the Danish trial were manageable. Adverse events were transient, generally mild to moderate gastrointestinal effects, and occurred more frequently in the semaglutide group. This aligns with the known side effect profile of semaglutide for weight loss.
Expanding Research Pipeline
The momentum behind GLP-1 research for addiction is building rapidly. A NIH-funded Phase 3 VA trial of semaglutide for AUD began enrolling on May 1, 2026, with estimated completion in April 2028. This larger study will test the approach in U.S. veterans, a population where comorbid anxiety, PTSD, and chronic pain often complicate traditional approaches.
Phase 3 trials evaluating semaglutide for AUD are underway, assessing its efficacy, tolerability, and safety, though the high cost may hinder widespread adoption. The Department of Veterans Affairs study will be particularly important because it will provide data on how well the treatment works in real-world clinical settings.
The American Psychiatric Association's 2026 Annual Meeting in San Francisco ran a session on GLP-1 agents in substance use treatment, reviewing the Fink-Jensen study alongside earlier signals from observational studies. This indicates the psychiatric community is taking these findings seriously.
Cost and Access Considerations
One major hurdle will be cost and insurance coverage. Currently, GLP-1 medications like Wegovy can cost $1,000+ per month without insurance. For alcohol use disorder treatment, insurance coverage would likely be even more limited since this would be an off-label use.
GLP-1 agonists are not yet FDA-approved for AUD, and prescribing them off-label for that indication carries the usual considerations around insurance coverage, gastrointestinal side effects, and the need for medical monitoring, but the research base is now strong enough that treating clinicians should know it exists.
Those seeking addiction treatment may want to compare telehealth providers to find clinicians knowledgeable about this emerging treatment option. Some providers may be willing to prescribe GLP-1 medications off-label for people with both obesity and alcohol use disorder.
Study Limitations and Next Steps
The Danish study had some limitations. Researchers noted that the study population was predominantly white, limiting generalisability, and called for greater efforts to include diverse populations in future trials, with longer-time follow-ups beyond 26 weeks.
Additionally, more research is needed to assess long-term effects and determine whether indefinite GLP-1 therapy may be needed to maintain benefits. This is similar to other chronic disease treatments where ongoing medication is required to maintain benefits.
One randomized phase 2 trial found that semaglutide significantly reduced drinking amounts and peak blood alcohol concentration during a self-administration task, and although it did not change the number of abstinence days, it reduced drinks on drinking days and lowered cravings.
What This Means for You
If you're struggling with alcohol use disorder and also have obesity, this research opens up a potentially important new treatment avenue. While semaglutide isn't yet FDA-approved for addiction treatment, the evidence is strong enough that it's worth discussing with a healthcare provider, especially if traditional treatments haven't worked for you.
If you tried medication-assisted treatment in the past and stopped, the landscape has shifted — the 2026 evidence base is meaningfully different from what was available even three years ago. The combination of treating both obesity and addiction with a single medication could be particularly valuable for people with both conditions.
To explore your options, you can find a clinic near you that offers comprehensive obesity and addiction treatment. Look for providers who stay current with the latest research and are comfortable with off-label prescribing when medically appropriate.
Sources
Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity - The Lancet study showing significant reduction in heavy drinking days
GLP-1 plus therapy can reduce heavy drinking - NIH summary of the Lancet trial results
Associations of semaglutide with incidence and recurrence of alcohol use disorder - Real-world observational study showing 50-56% risk reduction
GLP-1s for Alcohol Use Disorder: What the May 2026 Lancet Study Means - Clinical interpretation of the study findings
VA Clinical Trial: Semaglutide for Alcohol Use Disorder - Details on the ongoing Phase 3 Veterans Affairs study